NCT03305133

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 86 (actual)
• Sponsor: Groupe Francais De Pneumo-Cancerologie · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with large-cell lung neuroendocrine carcinoma (NEC), whatever the stage of the disease, and to correlate this parameter to clinical data at the time of diagnosis, therapeutic response and survival. Large-cell NECs present a bad prognostic and there is no evidence of treatment for these patients with advanced disease in second ligne of treatment at that time. To demonstrate the PD-L1 expression in this type of cancer might have a major therapeutic impact in a close future to access immunotherapies.

Conditions

• Large Cell Lung Cancer
• Neuroendocrine Carcinoma of Lung (Diagnosis)

Interventions

Type	Name	Description
OTHER	Immunohistochemistry	The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.

Timeline

• Start date: 2017-09-26
• Primary completion: 2018-09-14
• Completion: 2018-10-30
• First posted: 2017-10-09
• Last updated: 2020-03-12

Locations

28 sites across 1 country: France